loading
전일 마감가:
$12.60
열려 있는:
$12.7
하루 거래량:
80,023
Relative Volume:
0.49
시가총액:
$627.09M
수익:
-
순이익/손실:
$-119.67M
주가수익비율:
-8.5624
EPS:
-1.4105
순현금흐름:
$-97.30M
1주 성능:
-0.25%
1개월 성능:
-12.22%
6개월 성능:
-5.96%
1년 성능:
+101.66%
1일 변동 폭
Value
$12.04
$12.78
1주일 범위
Value
$11.30
$13.05
52주 변동 폭
Value
$5.85
$16.91

Mineralys Therapeutics Inc Stock (MLYS) Company Profile

Name
명칭
Mineralys Therapeutics Inc
Name
전화
(888) 378-6240
Name
주소
150 N. RADNOR CHESTER ROAD, RADNOR
Name
직원
28
Name
트위터
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
MLYS's Discussions on Twitter

MLYS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
MLYS 12.13 627.09M 0 -119.67M -97.30M -1.4105
VRTX 447.03 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.05 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 587.61 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.22 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.84 24.49B 3.30B -501.07M 1.03B 11.54

Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-03-07 개시 BofA Securities Buy
2023-03-07 개시 Credit Suisse Outperform
2023-03-07 개시 Evercore ISI Outperform
2023-03-07 개시 Guggenheim Buy
2023-03-07 개시 Stifel Buy
2023-03-07 개시 Wells Fargo Overweight
모두보기

Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스

pulisher
Nov 20, 2024

Mineralys Therapeutics Reports Q3 2024 Results and Clinical Progress - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Mineralys Therapeutics to Participate in Goldman Sachs Healthcare Conference - MSN

Nov 20, 2024
pulisher
Nov 18, 2024

Mineralys Therapeutics Set to Engage with Investors at Key Conferences - MSN

Nov 18, 2024
pulisher
Nov 14, 2024

Mineralys Therapeutics Inc (MLYS) Quarterly 10-Q Report - Quartzy

Nov 14, 2024
pulisher
Nov 14, 2024

What is Lifesci Capital's Forecast for MLYS FY2024 Earnings? - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

HC Wainwright Analysts Decrease Earnings Estimates for MLYS - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

(MLYS) Trading Signals - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

Mineralys therapeutics CMO sells shares worth $75,398 By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 13, 2024

MineralysTargeting Aldosterone To Combat Obesity-Driven Hypertension And Kidney Disease - RTTNews

Nov 13, 2024
pulisher
Nov 12, 2024

Mineralys Therapeutics Announces Q3 2024 Results and Updates - Yahoo Finance

Nov 12, 2024
pulisher
Nov 12, 2024

Mineralys Therapeutics' (MLYS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2024 Earnings Call Transcript - MSN

Nov 12, 2024
pulisher
Nov 11, 2024

Mineralys Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 11, 2024
pulisher
Nov 11, 2024

Mineralys Therapeutics reports Q3 EPS ($1.13), consensus (83c) - TipRanks

Nov 11, 2024
pulisher
Nov 11, 2024

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Nov 11, 2024
pulisher
Nov 09, 2024

David Malcom Rodman Sells 25,482 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Mineralys Therapeutics' chief medical officer sells $383,065 in stock - Investing.com

Nov 08, 2024
pulisher
Nov 07, 2024

Mineralys Therapeutics to Announce Third-Quarter 2024 Financial Results - MyChesCo

Nov 07, 2024
pulisher
Nov 05, 2024

Mineralys Therapeutics (MLYS) to Release Quarterly Earnings on Monday - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Mineralys Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Mineralys Therapeutics (MLYS) to Present at Three Major Healthcare Conferences | MLYS Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 04, 2024

Mineralys Therapeutics to Announce Third Quarter 2024 - GlobeNewswire

Nov 04, 2024
pulisher
Nov 04, 2024

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 - Marketscreener.com

Nov 04, 2024
pulisher
Nov 04, 2024

Mineralys Therapeutics’ (MLYS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Nov 04, 2024
pulisher
Nov 03, 2024

Objective long/short (MLYS) Report - Stock Traders Daily

Nov 03, 2024
pulisher
Nov 02, 2024

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial - MSN

Nov 02, 2024
pulisher
Oct 31, 2024

Mineralys Therapeutics (NASDAQ:MLYS) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

Mineralys Therapeutics : Corporate Overview October 2024 - Marketscreener.com

Oct 30, 2024
pulisher
Oct 30, 2024

Mineralys Therapeutics Advances Lorundrostat Trial Progress - TipRanks

Oct 30, 2024
pulisher
Oct 30, 2024

Mineralys Therapeutics Completes Enrollment Ahead of - GlobeNewswire

Oct 30, 2024
pulisher
Oct 30, 2024

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension - The Manila Times

Oct 30, 2024
pulisher
Oct 29, 2024

Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock - MSN

Oct 29, 2024
pulisher
Oct 25, 2024

Context Therapeutics to Engage Investors at November Conferences - MyChesCo

Oct 25, 2024
pulisher
Oct 24, 2024

Mineralys Therapeutics to Host Virtual Event on Hypertension Treatment Advances - MyChesCo

Oct 24, 2024
pulisher
Oct 23, 2024

When the Price of (MLYS) Talks, People Listen - Stock Traders Daily

Oct 23, 2024
pulisher
Oct 22, 2024

Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 - The Manila Times

Oct 22, 2024
pulisher
Oct 22, 2024

Mineralys to Host Virtual KOL Event on the Unmet Medical - GlobeNewswire

Oct 22, 2024
pulisher
Oct 20, 2024

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate - Yahoo Finance

Oct 20, 2024
pulisher
Oct 17, 2024

Hypertension Clinical Trials 2024: FDA Approvals, Medication, - openPR

Oct 17, 2024
pulisher
Oct 17, 2024

Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail

Oct 17, 2024
pulisher
Oct 16, 2024

Mineralys Therapeutics CEO sells $206,433 in stock - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Mineralys Therapeutics CEO sells $206,433 in stock By Investing.com - Investing.com Canada

Oct 16, 2024
pulisher
Oct 16, 2024

Mineralys therapeutics CFO Adam Levy sells $146,003 in stock By Investing.com - Investing.com South Africa

Oct 16, 2024
pulisher
Oct 16, 2024

Mineralys therapeutics CFO Adam Levy sells $146,003 in stock - Investing.com

Oct 16, 2024
pulisher
Oct 15, 2024

Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,271 Shares - GuruFocus.com

Oct 15, 2024
pulisher
Oct 15, 2024

Insider Sale: CFO Adam Levy Sells Shares of Mineralys Therapeuti - GuruFocus.com

Oct 15, 2024
pulisher
Oct 15, 2024

Adam Scott Levy Sells 10,757 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock - MarketBeat

Oct 15, 2024

Mineralys Therapeutics Inc (MLYS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
자본화:     |  볼륨(24시간):